{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:40:40Z","timestamp":1792190440032,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503522"],"award-info":[{"award-number":["82503522"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M771964"],"award-info":[{"award-number":["2025M771964"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The fibroinflammatory liver microenvironment (FILM), characterized by collagen-rich stroma and immunosuppressive inflammation, is prevalent in hepatocellular carcinoma (HCC) and correlates with poor response to programmed cell death protein 1 (PD-1) blockade. Here, we show that FILM suppresses gasdermin E (GSDME)-dependent pyroptosis and promotes immune suppression and anti-PD-1 resistance. Mechanistically, FILM-associated cancer-associated fibroblasts recruit and polarize macrophages toward a nitric oxide synthase 2 (NOS2)\u207a inflammatory phenotype. NOS2+ macrophage-derived nitric oxide induces SP1 S-nitrosylation, impairs SP1 binding to the peroxisome proliferator-activated receptor alpha (PPARA) promoter and transcriptionally represses PPARA in HCC cells. PPAR\u03b1 downregulation reduces pyruvate dehydrogenase kinase 4 (PDK4) expression, mitochondrial reactive oxygen species production, caspase-3 activation and GSDME cleavage. Conversely, ligand activation of tumor intrinsic PPAR\u03b1 restores the PDK4\u2013ROS\u2013caspase-3\u2013GSDME axis, enhances dendritic cell and CD8\u207a T cell activation, and sensitizes HCC to anti\u2013PD-1 therapy. The clinically approved PPAR\u03b1 agonist fenofibrate enhances anti-PD-1 efficacy in HCC models in male mice and is associated with improved clinical benefit in a retrospective cohort of patients with HCC. We propose a FILM\u2013NOS2\u2013SP1\u2013PPAR\u03b1\u2013PDK4 axis that controls pyroptotic immunogenicity and immunotherapy response, supporting PPAR\u03b1 activation as a strategy to overcome FILM-associated immune resistance in HCC.<\/jats:p>","DOI":"10.1038\/s41467-026-75770-7","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:44:36Z","timestamp":1786031076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PPAR\u03b1 activation overcomes fibroinflammatory liver microenvironment-associated anti-PD-1 resistance in hepatocellular carcinoma by mediating GSDME-dependent pyroptosis"],"prefix":"10.1038","volume":"17","author":[{"given":"Peng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuiyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0249-2411","authenticated-orcid":false,"given":"Junjie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunzi","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-7642","authenticated-orcid":false,"given":"Yongyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4094-3326","authenticated-orcid":false,"given":"Duo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-3600","authenticated-orcid":false,"given":"Yuchuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"75770_CR1","doi-asserted-by":"publisher","first-page":"102365","DOI":"10.1016\/j.coph.2023.102365","volume":"70","author":"F Peeters","year":"2023","unstructured":"Peeters, F. & Dekervel, J. Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma. Curr. Opin. Pharmacol. 70, 102365 (2023).","journal-title":"Curr. Opin. Pharmacol."},{"key":"75770_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/JHC.S347944","volume":"10","author":"A Laschtowitz","year":"2023","unstructured":"Laschtowitz, A., Roderburg, C., Tacke, F. & Mohr, R. Preoperative immunotherapy in hepatocellular carcinoma: current state of the art. J. Hepatocell. Carcinoma 10, 181\u2013191 (2023).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"75770_CR3","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau, T. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 6, e204564 (2020).","journal-title":"JAMA Oncol."},{"key":"75770_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.02.009","volume":"167","author":"M Kudo","year":"2022","unstructured":"Kudo, M., Finn, R. S. & Edeline, J. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur. J. Cancer 167, 1\u201312 (2022).","journal-title":"Eur. J. Cancer"},{"key":"75770_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa, L., Finn, R. S. & Sangro, B. Combination immunotherapy for hepatocellular carcinoma. J. Hepatol. 79, 506\u2013515 (2023).","journal-title":"J. Hepatol."},{"key":"75770_CR6","doi-asserted-by":"publisher","first-page":"101130","DOI":"10.1016\/j.jhepr.2024.101130","volume":"6","author":"A Childs","year":"2024","unstructured":"Childs, A., Aidoo-Micah, G. & Maini, M. K. Immunotherapy for hepatocellular carcinoma. JHEP Rep. 6, 101130 (2024).","journal-title":"JHEP Rep."},{"key":"75770_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"AL Cheng","year":"2020","unstructured":"Cheng, A. L., Hsu, C., Chan, S. L., Choo, S. P. & Kudo, M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J. Hepatol. 72, 307\u2013319 (2020).","journal-title":"J. Hepatol."},{"key":"75770_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 402, 1133\u20131146 (2023).","journal-title":"Lancet"},{"key":"75770_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000538558","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo, M. Immune checkpoint inhibitors plus anti-VEGF\/tyrosine kinase inhibitors combined with TACE (triple therapy) in unresectable hepatocellular carcinoma. Liver Cancer 13, 227\u2013234 (2024).","journal-title":"Liver Cancer"},{"key":"75770_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Prim"},{"key":"75770_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich, L. & Tacke, F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 20, 633\u2013646 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"75770_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-025-00798-8","volume":"25","author":"Z Xiao","year":"2025","unstructured":"Xiao, Z. & Pur\u00e9, E. The fibroinflammatory response in cancer. Nat. Rev. Cancer 25, 399\u2013425 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"75770_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D., N\u00fa\u00f1ez, N. G. & Pinyol, R. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450\u2013456 (2021).","journal-title":"Nature"},{"key":"75770_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/gutjnl-2018-317257","volume":"69","author":"M Liu","year":"2020","unstructured":"Liu, M. et al. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut 69, 365\u2013379 (2020).","journal-title":"Gut"},{"key":"75770_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2022.09.012","volume":"31","author":"X Liu","year":"2023","unstructured":"Liu, X., Zhou, J. & Wu, H. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma. Mol. Ther. 31, 119\u2013133 (2023).","journal-title":"Mol. Ther."},{"key":"75770_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","volume":"535","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153\u2013158 (2016).","journal-title":"Nature"},{"key":"75770_CR17","doi-asserted-by":"crossref","unstructured":"Inkol, J. M. et al. Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells. J. Immunother. Cancer 12, e006781 (2024).","DOI":"10.1136\/jitc-2023-006781"},{"key":"75770_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415\u2013420 (2020).","journal-title":"Nature"},{"key":"75770_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14128","volume":"8","author":"C Rogers","year":"2017","unstructured":"Rogers, C. et al. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death. Nat. Commun. 8, 14128 (2017).","journal-title":"Nat. Commun."},{"key":"75770_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax7969","volume":"5","author":"Y Liu","year":"2020","unstructured":"Liu, Y., Fang, Y. & Chen, X. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci. Immunol. 5, eaax7969 (2020).","journal-title":"Sci. Immunol."},{"key":"75770_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13046-021-02065-8","volume":"40","author":"R Loveless","year":"2021","unstructured":"Loveless, R., Bloomquist, R. & Teng, Y. Pyroptosis at the forefront of anticancer immunity. J. Exp. Clin. Cancer Res. 40, 264 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"75770_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101796","volume":"39","author":"X Liang","year":"2024","unstructured":"Liang, X. et al. GSDME has prognostic and immunotherapeutic significance in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Transl. Oncol. 39, 101796 (2024).","journal-title":"Transl. Oncol."},{"key":"75770_CR23","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.apsb.2020.06.015","volume":"10","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis. Acta Pharm. Sin. B 10, 1397\u20131413 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"75770_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne, D., Butruille, L. & Staels, B. PPAR control of metabolism and cardiovascular functions. Nat. Rev. Cardiol. 18, 809\u2013823 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"75770_CR25","doi-asserted-by":"publisher","first-page":"109212","DOI":"10.1016\/j.celrep.2021.109212","volume":"35","author":"MD Mana","year":"2021","unstructured":"Mana, M. D. et al. High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity. Cell Rep. 35, 109212 (2021).","journal-title":"Cell Rep."},{"key":"75770_CR26","doi-asserted-by":"publisher","first-page":"107447","DOI":"10.1016\/j.jbc.2024.107447","volume":"300","author":"Q Gou","year":"2024","unstructured":"Gou, Q. et al. PPAR\u03b1 phosphorylation regulates colorectal tumor immune escape.  J. Biol. Chem. 300, 107447 (2024).","journal-title":"J. Biol. Chem."},{"key":"75770_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18042","volume":"28","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y., Tan, H., Zhang, X. & Zhu, J. Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma. J. Cell. Mol. Med. 28, e18042 (2024).","journal-title":"J. Cell. Mol. Med."},{"key":"75770_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2412473122","volume":"122","author":"X Qian","year":"2025","unstructured":"Qian, X., Zhou, Q. & Ouyang, Y. Transferrin promotes fatty acid oxidation and liver tumor growth through PHD2-mediated PPAR\u03b1 hydroxylation in an iron-dependent manner. Proc. Natl. Acad. Sci. USA 122, e2412473122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75770_CR29","doi-asserted-by":"publisher","first-page":"166974","DOI":"10.1016\/j.bbadis.2023.166974","volume":"1870","author":"W Liu","year":"2024","unstructured":"Liu, W., Wang, S. & Lin, L. BAP18 acting as a novel peroxisome proliferator-activated receptor \u03b1 co-regulator contributes to hepatocellular carcinoma progression. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 166974 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"75770_CR30","doi-asserted-by":"publisher","first-page":"101228","DOI":"10.1016\/j.jhepr.2024.101228","volume":"7","author":"B Pan","year":"2025","unstructured":"Pan, B. et al. PPAR\u03b1 suppresses growth of hepatocellular carcinoma in a high-fat diet context by reducing neutrophil extracellular trap release. JHEP Rep. 7, 101228 (2025).","journal-title":"JHEP Rep."},{"key":"75770_CR31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cmet.2024.04.015","volume":"36","author":"S Gallage","year":"2024","unstructured":"Gallage, S., Ali, A. & Barragan, A. J. E. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR\u03b1 and PCK1. Cell Metab. 36, 1371\u20131393.e7 (2024).","journal-title":"Cell Metab."},{"key":"75770_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cell.2009.05.036","volume":"138","author":"MV Chakravarthy","year":"2009","unstructured":"Chakravarthy, M. V. et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138, 476\u2013488 (2009).","journal-title":"Cell"},{"key":"75770_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/cancers12030641","volume":"12","author":"MG Refolo","year":"2020","unstructured":"Refolo, M. G., Messa, C. & Guerra, V. Inflammatory mechanisms of HCC development. Cancers 12, 641 (2020).","journal-title":"Cancers"},{"key":"75770_CR34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A., Kotlov, N. & Nomie, K. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e7 (2021).","journal-title":"Cancer Cell"},{"key":"75770_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue, R., Zhang, Q. & Cao, Q. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612, 141\u2013147 (2022).","journal-title":"Nature"},{"key":"75770_CR36","doi-asserted-by":"publisher","first-page":"103847","DOI":"10.1016\/j.isci.2022.103847","volume":"25","author":"JC McVey","year":"2022","unstructured":"McVey, J. C. et al. NAFLD indirectly impairs antigen-specific CD8(+) T cell immunity against liver cancer in mice. iScience 25, 103847 (2022).","journal-title":"iScience"},{"key":"75770_CR37","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"75770_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0048-z","volume":"2","author":"LX Yu","year":"2018","unstructured":"Yu, L. X., Ling, Y. & Wang, H. Y. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis. Oncol. 2, 6 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"75770_CR39","doi-asserted-by":"publisher","first-page":"612139","DOI":"10.3389\/fimmu.2021.612139","volume":"12","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y. et al. TANK-binding kinase 1 (TBK1) serves as a potential target for hepatocellular carcinoma by enhancing tumor immune infiltration. Front. Immunol. 12, 612139 (2021).","journal-title":"Front. Immunol."},{"key":"75770_CR40","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/jcmm.16256","volume":"25","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y. et al. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. J. Cell. Mol. Med. 25, 1568\u20131582 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"75770_CR41","doi-asserted-by":"publisher","first-page":"44837","DOI":"10.31083\/FBL44837","volume":"12","author":"YA Qu","year":"2025","unstructured":"Qu, Y. A. et al. Understanding the cancer-associated fibroblast (CAF) and its biomarker fibroblast activation protein (FAP), and aspects in human liver cancer. Front. Biosci. (Landmark Ed.) 30, 44837 (2025).","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"75770_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-021-01959-x","volume":"40","author":"Y Tan","year":"2021","unstructured":"Tan, Y. et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J. Exp. Clin. Cancer Res. 40, 153 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"75770_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101840","volume":"8","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. et al. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy. Adv. Sci. 8, 2101840 (2021).","journal-title":"Adv. Sci."},{"key":"75770_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s42003-022-03806-x","volume":"5","author":"X Lou","year":"2022","unstructured":"Lou, X. et al. Pyroptosis correlates with tumor immunity and prognosis. Commun. Biol. 5, 917 (2022).","journal-title":"Commun. Biol."},{"key":"75770_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.815290","volume":"9","author":"Y Yan","year":"2022","unstructured":"Yan, Y. et al. Pyroptosis-related patterns predict tumor immune landscape and immunotherapy response in bladder cancer. Front Mol. Biosci. 9, 815290 (2022).","journal-title":"Front Mol. Biosci."},{"key":"75770_CR46","doi-asserted-by":"crossref","unstructured":"Cao, Q. et al. GSDME\u2013IL-18 pyroptotic axis prevents myosteatosis by expanding tissue-resident macrophages to promote muscle regeneration. J. Clin. Invest. 136, e198076 (2026).","DOI":"10.1172\/JCI198076"},{"key":"75770_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62071-8","volume":"16","author":"Q Chen","year":"2025","unstructured":"Chen, Q. et al. Renal tubular GSDME protects cisplatin nephrotoxicity by impeding OGT-STAT3-S100A7A axis in male mice. Nat. Commun. 16, 6807 (2025).","journal-title":"Nat. Commun."},{"key":"75770_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66103-1","volume":"16","author":"SJ Sun","year":"2025","unstructured":"Sun, S. J. et al. GSDME-dependent pyroptosis drives abdominal aortic aneurysm via promoting vascular senescence. Nat. Commun. 16, 11248 (2025).","journal-title":"Nat. Commun."},{"key":"75770_CR49","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cmet.2025.12.017","volume":"38","author":"N Ding","year":"2026","unstructured":"Ding, N. et al. Gut microbiota-derived isovaleric acid alleviates atrial fibrillation by suppressing GSDME-dependent pyroptosis. Cell Metab. 38, 370\u2013387.e10 (2026).","journal-title":"Cell Metab."},{"key":"75770_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1172\/JCI27989","volume":"116","author":"P Lefebvre","year":"2006","unstructured":"Lefebvre, P., Chinetti, G., Fruchart, J. C. & Staels, B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571\u2013580 (2006).","journal-title":"J. Clin. Invest."},{"key":"75770_CR51","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cmet.2005.04.002","volume":"1","author":"MV Chakravarthy","year":"2005","unstructured":"Chakravarthy, M. V. et al. \u201cNew\u201d hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 1, 309\u2013322 (2005).","journal-title":"Cell Metab."},{"key":"75770_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1441-4","volume":"10","author":"J Yu","year":"2019","unstructured":"Yu, J. et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 10, 193 (2019).","journal-title":"Cell Death Dis."},{"key":"75770_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10238-022-00799-z","volume":"23","author":"AB Chowdhury","year":"2023","unstructured":"Chowdhury, A. B. & Mehta, K. J. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin. Exp. Med. 23, 273\u2013285 (2023).","journal-title":"Clin. Exp. Med."},{"key":"75770_CR54","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/cld.1014","volume":"17","author":"M Krishna","year":"2021","unstructured":"Krishna, M. Histological grading and staging of chronic hepatitis. Clin. Liver Dis. 17, 222\u2013226 (2021).","journal-title":"Clin. Liver Dis."},{"key":"75770_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902880","volume":"7","author":"YR Miao","year":"2020","unstructured":"Miao, Y. R. et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv. Sci. 7, 1902880 (2020).","journal-title":"Adv. Sci."},{"key":"75770_CR56","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1038\/s41388-021-02024-9","volume":"40","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer. Oncogene 40, 6381\u20136393 (2021).","journal-title":"Oncogene"},{"key":"75770_CR57","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J. Hepatol. 78, 770\u2013782 (2023).","journal-title":"J. Hepatol."},{"key":"75770_CR58","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/HEP.0000000000000623","volume":"80","author":"P Chen","year":"2024","unstructured":"Chen, P. et al. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for HCC. Hepatology 80, 330\u2013345 (2024).","journal-title":"Hepatology"},{"key":"75770_CR59","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/s12276-025-01556-4","volume":"57","author":"Z Dong","year":"2025","unstructured":"Dong, Z. et al. The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination. Exp. Mol. Med. 57, 2317\u20132330 (2025).","journal-title":"Exp. Mol. Med."},{"key":"75770_CR60","doi-asserted-by":"crossref","unstructured":"Jaffrey, S. R. & Snyder, S. H. The biotin switch method for the detection of S-nitrosylated proteins. Sci. STKE 2001, pl1 (2001).","DOI":"10.1126\/stke.2001.86.pl1"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75770-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75770-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75770-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:47:19Z","timestamp":1788475639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75770-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75770"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75770-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9474"}}